Moreover, when evaluating the combined use of serum IL-6 and CYFRA 21-1 between the LC and HR groups, and serum IL-6 and IL-8 between the LC and HC groups (Figure 3A,B), the diagnostic performance of these biomarkers for LC risk becomes apparent. This evidence concerns the gene IL6 and laryngotracheoesophageal cleft.